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SUMMARY 
 Reports of the beneficial effects of the hypnotic imidazopyridine, zolpidem, 
described in persistent vegetative state1, 2 have been replicated recently in brain-
injured and cognitively impaired patients3-7. Previous single photon emission 
computed tomography (SPECT) studies have suggested that sub-sedative doses of 
zolpidem increased regional cerebral perfusion in affected areas5, 8, implying 
enhanced neuronal metabolic activity; which has led to speculation that zolpidem 
‘reawakens’ functionally dormant cortex. However, a neuronal mechanism by which 
this hypnotic drug affords benefits to brain injured patients has yet to be 
demonstrated. 
  Here, we report the action of sub-sedative doses of zolpidem on neuronal 
network oscillatory activity in human brain, measured using pharmaco-
magnetoencephalography (pharmaco-MEG). Study participant JP suffered a stroke 
in 1996, causing major damage to the left hemisphere that impaired aspects of both 
motor and cognitive function. Pharmaco-MEG analyses revealed robust and 
persistent pathological theta (4-10Hz) and beta (15-30Hz) oscillations within the 
lesion penumbra and surrounding cortex.  Administration of zolpidem (5mg) 
reduced the power of pathological theta and beta oscillations in all regions of the 
lesioned hemisphere. This desynchronizing effect correlated well with zolpidem 
uptake (occurring approximately 40 minutes after acute administration) and was 
coincident with marked improvements in cognitive and motor function. Control 
experiments revealed no effect of placebo, while a structurally unrelated hypnotic, 
zopiclone, administered at a comparable dose (3.5mg) elicited widespread 
increases in cortical oscillatory power in the beta (15-30Hz) band without functional 
improvement. These results suggest that in JP, specific motor and cognitive 
impairments are related to increased low-frequency oscillatory neuronal network 
activity. Zolpidem is unique amongst hypnotic drugs in its ability to desynchronize 
such pathological low-frequency activity, thereby restoring cognitive function. 
The family of ‘z drugs’ which includes zolpidem, zopiclone and zaleplon are 
non-benzodiazepine sedative/hypnotic agents usually prescribed (10-30mg) for 
insomnia9, 10, taking advantage of their fast absorption, short half-life and resultant 
limited duration of action.  However, over recent years there have been an 
increasing number of reports that have highlighted the paradoxical ability of sub-
sedative doses (2-5mg) of zolpidem to improve cognitive and motor ability for 
patients not only in persistent vegetative state1, but also in brain injury5, 7, idiopathic 
Parkinson’s disease11, drug-induced Parkinsonism3, and dementia4. 
 Previous single photon emission computed tomography (SPECT) studies 
have suggested that there is reduced regional blood perfusion in the affected brain 
area, with respect to the contralateral hemisphere, suggestive of diminished 
neuronal activity. Following administration of low-dose zolpidem, SPECT studies in 
a brain injured patient showed increased perfusion, implying recovery of cortical 
activity5. 
 Here we report results from participant JP, who suffered a major stroke 12 
years ago.  JP presented with fluent conversational speech but had difficulties 
comprehending specific words (a specific auditory-verbal deficit) with word finding 
difficulties and semantic paraphasias. Unilateral somatosensory diminution and 
abnormal gait were also observed. JP evinced marked cognitive and motor 
improvement in response to zolpidem (5mg), such that a single daily dose provided 
symptomatic relief beginning at approximately 40 minutes and lasting for up to 8 
hours, consistent with previous reports1, 5. In addition to symptomatic relief, 
previous psychometric assessment of JP suggested improvements in IQ as a 
consequence of zolpidem administration, although the specific nature of this 
amelioration was not identified. Similarly, initial SPECT imaging suggested a 
reduced cerebrovascular perfusion in posterior left temporal lobe, which was 
improved following zolpidem administration (Fig. 1a & b). These initial observations 
formed the starting-point for the studies on JP described below, the ultimate 
purpose of which was to determine the changes in brain activity underlying JP’s 
neurological deficits and, more importantly, to measure how network activity was 
modulated by zolpidem in relation to recovery of sensorimotor and cognitive 
function.  
We used a multimodal imaging approach, comprising magnetic resonance 
imaging (MRI) and proton magnetic resonance spectroscopy (1H MRS) to obtain 
structural and chemical information from stroke-affected and unaffected brain 
regions (Fig. 1c-g). Spatial information from these scans was used to guide 
subsequent magnetoencephalography (MEG) investigation through placement of 
‘virtual electrodes’ in anatomically defined loci to determine the profile of focal 
electrical activity across the cortex prior to, and following drug administration.  
Initial observations from 99mTc-hexamethylpropylene amine oxime (HMPAO) 
SPECT of reduced left temporal lobe perfusion (Fig. 1a), which were improved by 
zolpidem administration (Fig. 1b), were contextualized by the visualization of the 
left lateralized lesion using MRI (Fig 1c). A generalized partially parallel acquisition 
(GRAPPA) image of a T2-weighted scan of JP in the sagittal plane (Fig. 1d) 
revealed the extent of the left temporal lobe lesion, impinging on language and 
motor areas. Grey and white matter visualization was used to identify regions for 
further analysis within the lesion, the intact contralateral hemisphere and the lesion 
penumbra (denoted A, B and C respectively). Subsequently, using co-registration 
with the anatomical MRI12, these loci were investigated using MRS and MEG. MRS 
analysis of the lesion site revealed an absence of typical metabolic markers 
associated with viable brain tissue, such as N-acetyl-aspartate (NAA), creatine (Cr), 
choline (Ch) and myo-inositol (mI), although a lactate (Lac) peak, commonly seen 
in cerebrospinal fluid (CSF) could be seen (Fig. 1e). Investigation of the 
contralateral hemisphere revealed a typical chemical spectral profile, with normal 
ratios of NAA, Cr, Cho and mI (Fig. 1f). However, whilst the lesion penumbra 
location also showed relatively normal ratios of these metabolites, the spectrum 
was dominated by an abnormally high Lac peak (Fig. 1g), suggesting a degree of 
ongoing metabolic stress within neuronal populations close to the original lesion. 
MEG virtual electrode analysis, derived from the Synthetic Aperture 
Magnetometry (SAM) beamforming method13, was used to derive power-spectra 
from the voxels used in MRS analysis (1-60Hz). A MEG signal was not detectable 
in the lesion voxel (Fig. 1h), whereas the contralateral voxel was typified by a 
normal amplitude spectrum with moderate power across the low-frequency range 
(Fig. 1i). Analysis of the penumbral voxel revealed strikingly high power in the theta 
frequency range (peak 8Hz) superimposed on a high degree of broadband low-
frequency oscillatory activity (Fig. 1j). This pattern of slow wave activity, seen first in 
the lesion penumbra, was evident across all virtual electrode placements ipsilateral 
to the lesion, including the dorsolateral prefrontal cortex (DLPFC), parietal lobe, 
superior temporal lobe and sensorimotor cortex (SMC), and was not evident in 
contralateral electrodes. Furthermore, in the ipsilateral sensorimotor regions 
adjacent to the lesion an elevated beta frequency oscillation (peak 25Hz) was also 
evident (Fig. 2c & k).  
 
Figure 1 Here 
 
Double blind, placebo controlled pharmaco-MEG analyses of a 60 minute 
period following drug administration, used SAM techniques13, 14 to identify the 
spatial distribution of power change in delta (1-3Hz), theta (4-10Hz), alpha (7-
14Hz), beta (15-30Hz) and gamma (30-80Hz) frequency bands. This approach 
revealed a powerful desynchronizing effect of zolpidem on the enhanced theta and 
beta activity seen within ipsilateral cortex, in both language-associated (Fig.2a & e; 
Fig. 3b) and sensorimotor areas (Fig. 2c & f; Fig 3a). By contrast, we observed no 
effects of zolpidem on baseline low-frequency activity in electrodes placed 
contralateral to the lesion (Fig.2b & d). When we repeated these experiments using 
a placebo we observed no effects on MEG activity. Conversely, following zopiclone 
administration at sub-sedative dose (3.5 mg), we noted a striking, bilateral, 
broadband increase (Fig. 2g-l) in oscillatory activity in the beta frequency range 
(15-30 Hz), consistent with previous MEG observations using a similarly non-
specific GABAA receptor modulator15. These data indicate that 12 years following 
initial insult, neuronal tissue surrounding the original lesion continues to exhibit 
pathological behavior in the form of slow wave oscillations and also that zolpidem 
has a unique, desynchronizing effect that is specific to such activity. 
 Figure 2 Here 
 
We next addressed the question of how focal desynchronization was related 
to cognitive and sensorimotor function in JP through MEG measures of language 
and motor function. The use of independent isometric contraction of the left and 
right hands afforded localization of respective contralateral SMC through peak beta 
frequency desynchronization (Fig. 3i) consistent with previous observations16. 
Similarly, category naming and covert letter fluency tasks were employed to 
localize language related areas through peak desynchronization (Fig. 3j & k), 
consistent with previous observations in the DLPFC17. These latter activations were 
key, since these tasks typify the language difficulty that JP exhibited under drug-
free conditions. We found a strong spatial and frequency domain correspondence 
between the zolpidem-induced (Fig. 3a & b) and functional desynchronization 
events (Fig. 3i-k), suggesting that zolpidem administration had direct functional 
consequences within modalities in which JP is compromised.  
With the aim of identifying the temporal profile of oscillatory changes that 
underlie the improvements in cognitive and sensorimotor performance, we 
implemented a virtual electrode reconstruction of discrete neuronal activity at the 
peaks of desynchronization in both the passively and functionally identified loci. 
This method is a measure of discrete neuronal activity18 resembling those made at 
the local field potential level19. We reconstructed the envelope of oscillatory power 
over the entire 60 minute duration following drug administration. This approach 
revealed that the abnormally high sensorimotor beta oscillations observed prior to 
drug uptake were persistent, and were chronically suppressed following zolpidem 
administration (Fig. 3c & f). Similarly, abnormally high and persistent theta 
oscillations observed in language performance areas such as DLPFC were also 
suppressed by zolpidem (Fig. 3d, e, g & h).  
 
Figure 3 Here 
 
The onset of these reductions in synchronous power occurred at 35-45 
minutes post drug administration, consistent with both JP’s self-reported 
improvements on language-related tasks and the pharmacokinetic profile of 
zolpidem. Neither the therapeutic benefit nor the associated desynchronization was 
observed following administration of zopiclone or placebo. Psychometric evaluation 
of JP used the WAIS-III22 to evaluate drug-enhanced cognitive performance, firstly 
with zolpidem and then 6 months later without zolpidem. Test-retest gains in 
performance across WAIS-III Index and IQ scores due to practice effects are well 
documented20. Therefore, the order of administration was chosen to underestimate 
rather than overestimate gains due to zolpidem. JP achieved highest scores on the 
Perceptual Organization Index, with scores falling in the top 12-18% of his age 
group. In the absence of zolpidem results revealed deterioration in performance 
across all Index and IQ scores with the exception of the Working Memory Index, 
which remained within the bottom 1% of the population across both test occasions. 
The greatest change was evident in the Verbal Comprehension Index and JP’s 
standardized score dropped by 27 percentile points, moving from the ‘average’ to 
the ‘low average’ range (Fig. 4); these observations were consistent with clinical 
presentation. 
 
Figure 4 Here 
 
In summary, in JP, a left temporal lesion resulted in an increase in 
pathological theta and beta frequency oscillatory power compared to the 
undamaged contralateral hemisphere. In sub-sedative doses, zolpidem was 
capable of suppressing pathological slow wave activity to a level that allowed 
functionality to return. It seems reasonable to infer that the action of zolpidem in 
brain injury is related to its unique dose-dependent selectivity for GABAA receptors 
containing the α-1 subunit. The desynchronizing effect of zolpidem may reflect the 
differential distribution of α-1 subunit containing GABAA receptors between specific 
interneuronal subtypes sub-serving oscillatory activity21. Consistent with this 
interpretation, non-selective GABAA receptor modulators such as lorazepam15 and 
zopiclone do not desynchronize neuronal network activity, indeed, oscillatory power 
is enhanced. 
Synchronization across extensive neuronal populations can result in a 
marked reduction in information transfer. Specifically, a broad elevation in the 
mutual information between cortical regions will reduce the capacity for 
computational processing. In this scenario, the consequent reduction in the 
complexity of information encoding would provide an explanation for the cognitive 
decline observed under pathological conditions.  Exaggerated slow wave activity is 
a feature common to a diverse array of neuropathologies, including traumatic brain 
injury22, stroke23, Alzheimer’s disease24, and schizophrenia25 and therefore may 
represent a biomarker for impaired CNS functionality. Desynchronization of 
pathological oscillatory activity appears to improve CNS function. For example, in 
Parkinson’s disease, dopamine replacement therapy has been demonstrated to 
reverse augmented beta activity, which correlates with symptomatic relief11, 26. 
Similarly, administration of dopamine agonists is efficacious in the treatment of 
brain injury27. Furthermore, following deep brain stimulation positive functional 
outcomes linked to a desynchronization of EEG oscillatory activity have been 
observed in persistent vegetative state28.  
It is widely accepted that event-related desynchronization (ERD) is a central 
phenomenon in normal brain activity29 and ERD has been established as a feature 
of sensorimotor16 and cognitive processing17. In JP, the high power and persistent 
nature of pathological oscillations appears to represent an obstacle to adequate 
ERD; this inability to desynchronize may represent a barrier to effective 
computation in neuronal networks. Here we show that drug induced suppression of 
this functional barrier affords a return of cognitive performance, typically associated 
with ERD. As previous evidence suggests, MEG is an optimal tool for the 
identification of slow wave activity22 as a biomarker of brain dysfunction. In addition, 
we would suggest that pharmaco-MEG represents a powerful method for the 
identification and development of future therapeutic interventions. 
In conclusion, given the involvement of pathological slow wave oscillatory 
activity in a wide range of neurological disorders, and the desynchronizing 
properties of zolpidem as measured using pharmaco-MEG, it seems reasonable to 
suggest that zolpidem treatment might prove to have a broad therapeutic remit. 
 
Methods Summary 
Our participant, JP, presented with sensorimotor and language deficits 
following major stroke, which were reported to improve following single daily 
administration of zolpidem. SPECT analysis was used to determine regional 
perfusion with and without zolpidem. We used structural MRI scans to determine 
the spatial extent of the lesion and to obtain detailed anatomical information for 
functional co-registration. Voxels were identified with the left temporal lesion, the 
lesion penumbra and comparative location contralateral to the lesion. These three 
voxels were examined using MRS and MEG to identify the chemical composition 
and power spectra respectively. 
JP was tested using a double blind drug study over three days to examine 
the effects, over a 60 minute period, of zolpidem (5mg), zopiclone (3.5mg) and 
placebo on intrinsic oscillatory activity across the cortex. MEG data were co-
registered with JP’s anatomical MRI12 and analysis was performed using a SAM 
beamforming method13, 14 to identify peaks of synchronous power change in 
response to each of the drugs administered. Additionally, a number of functional 
tasks were used to localize sensorimotor and language related areas16, 17.  
At the peaks of oscillatory power change, identified from SAM analysis, 
virtual electrodes were implemented in order to identify the power spectra at the 
loci pre and post drug. Furthermore, the electrical signals from these loci were 
band-pass filtered to the peak frequencies in the theta and beta ranges and the 
envelope of the oscillatory power30 reconstructed for the 60 minute duration 
following drug administration. In order to establish the exact nature of JP’s cognitive 
impairments and improvements following zolpidem, a comprehensive psychometric 
evaluation was performed using the WAIS-III. These were undertaken firstly with 
zolpidem and then 6 months later without zolpidem, to account for potential practice 
effects. 
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Figure Legends 
 
Figure 1 ⏐ Characterization of pathology. SPECT analysis showing cerebral 
blood perfusion (a) before and (b) after zolpidem; white boxes indicate left temporal 
region where perfusion is increased. MRI images showing the extent of the lesion 
in the left hemisphere in (c) a T1 weighted sagittal section and (d) T2 weighted 
axial section; red boxes (A, B & C) indicate lesion, contralateral control and lesion 
penumbra voxels used for subsequent MRS and MEG analyses. MRS analysis of 
voxels identified from MRI (e, f & g derived from A, B & C respectively); 
abbreviated annotations indicate chemical markers observed. MEG analysis of 
voxels A, B & C (h, i & j respectively), showing power spectral analyses (0-60Hz).  
 
Figure 2⏐ Drug induced oscillatory modulation. Results of SAM analyses 
indicating the spatial distribution of oscillatory power change as a consequence of 
zolpidem (a & b) and zopiclone (k & l) administration; blue indicates a reduction 
and orange an increase in oscillatory power. a, theta desynchronization and b, beta 
desynchronization following zolpidem administration. Power spectral change in left 
and right DLPFC (c & d) and left and right SMC (e & f) pre and post zolpidem 
administration. Beta synchronization bilaterally in frontal cortex (k) and SMC (l), pre 
and post zopiclone administration. Power spectral change bilaterally in DLPFC (g & 
h) and SMC (I & j), pre and post zopiclone administration. 
 
Figure 3 ⏐ Pharmacodynamic profile of zolpidem induced desynchronization. 
SAM and images co-registered with the 3-dimensional MRI and band-pass filtered 
virtual electrode traces recorded for 60 minutes post zolpidem administration. 
Distribution and time-course of desynchronization in the beta (a & c) and theta (b, d 
& e) frequencies. Event-related desynchronization (ERD) in the beta range in 
response to contraction of the right hand (i) and in the theta range in response to 
category naming (j) and covert letter fluency tasks. Virtual Electrode analysis 
indicates the electrical activity at these peak ERD loci over the 60 minutes duration, 
band-pass filtered to beta (f) and theta (g & h). Red lines denote onset of zolpidem-
induced cognitive and motor improvements. 
 
Figure 4 ⏐ Psychometric analysis of zolpidem mediated improvement. Bar 
chart reflecting the results of JP’s WAIS-III assessments carried out with zolpidem 
(blue) and without zolpidem (red). Scores are age-standardized and displayed as 
percentiles. 
 
 




